Cencora, Inc. $COR Shares Sold by Mattern Capital Management LLC

Mattern Capital Management LLC decreased its holdings in shares of Cencora, Inc. (NYSE:COR) by 6.2% in the third quarter, Holdings Channel reports. The firm owned 44,049 shares of the company’s stock after selling 2,928 shares during the quarter. Cencora comprises about 1.6% of Mattern Capital Management LLC’s portfolio, making the stock its 4th biggest holding. Mattern Capital Management LLC’s holdings in Cencora were worth $13,767,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of COR. State of Wyoming lifted its position in shares of Cencora by 15.2% during the 1st quarter. State of Wyoming now owns 742 shares of the company’s stock worth $206,000 after buying an additional 98 shares during the period. Aprio Wealth Management LLC boosted its stake in shares of Cencora by 10.2% in the 1st quarter. Aprio Wealth Management LLC now owns 1,142 shares of the company’s stock valued at $318,000 after purchasing an additional 106 shares in the last quarter. Ancora Advisors LLC grew its holdings in shares of Cencora by 8.1% in the 1st quarter. Ancora Advisors LLC now owns 4,191 shares of the company’s stock worth $1,166,000 after purchasing an additional 314 shares during the last quarter. Amundi increased its position in shares of Cencora by 9.8% during the 1st quarter. Amundi now owns 1,470,536 shares of the company’s stock worth $425,514,000 after purchasing an additional 131,826 shares in the last quarter. Finally, Advisors Asset Management Inc. lifted its holdings in Cencora by 3.7% during the 1st quarter. Advisors Asset Management Inc. now owns 14,611 shares of the company’s stock valued at $4,063,000 after purchasing an additional 526 shares during the last quarter. 97.52% of the stock is currently owned by institutional investors.

Cencora Stock Down 0.6%

NYSE:COR opened at $338.07 on Friday. The stock’s fifty day moving average price is $349.47 and its two-hundred day moving average price is $316.22. The company has a market cap of $65.58 billion, a price-to-earnings ratio of 42.52, a P/E/G ratio of 1.61 and a beta of 0.66. Cencora, Inc. has a 52-week low of $223.92 and a 52-week high of $377.54. The company has a debt-to-equity ratio of 4.32, a quick ratio of 0.55 and a current ratio of 0.90.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 EPS for the quarter, topping analysts’ consensus estimates of $3.79 by $0.05. Cencora had a return on equity of 227.15% and a net margin of 0.48%.The firm had revenue of $83.73 billion during the quarter, compared to analyst estimates of $83.36 billion. During the same period last year, the company earned $3.34 earnings per share. The company’s revenue was up 5.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. On average, analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, December 1st. Stockholders of record on Friday, November 14th were paid a $0.60 dividend. This is an increase from Cencora’s previous quarterly dividend of $0.55. The ex-dividend date of this dividend was Friday, November 14th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.7%. Cencora’s dividend payout ratio (DPR) is currently 30.19%.

Insider Transactions at Cencora

In other Cencora news, EVP Elizabeth S. Campbell sold 3,351 shares of the firm’s stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $342.10, for a total transaction of $1,146,377.10. Following the transaction, the executive vice president owned 23,891 shares in the company, valued at approximately $8,173,111.10. This trade represents a 12.30% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Robert P. Mauch sold 5,097 shares of the business’s stock in a transaction dated Monday, October 20th. The stock was sold at an average price of $326.80, for a total value of $1,665,699.60. Following the transaction, the chief executive officer owned 37,940 shares of the company’s stock, valued at $12,398,792. The trade was a 11.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 20,317 shares of company stock worth $7,009,260 in the last three months. Insiders own 10.80% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on COR. Mizuho upped their price objective on shares of Cencora from $340.00 to $380.00 and gave the stock an “outperform” rating in a research note on Thursday, November 6th. JPMorgan Chase & Co. increased their price target on Cencora from $344.00 to $417.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 11th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Cencora in a report on Monday. Wells Fargo & Company boosted their price objective on Cencora from $354.00 to $405.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 11th. Finally, Wall Street Zen lowered Cencora from a “buy” rating to a “hold” rating in a research note on Friday, November 28th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $373.25.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.